The research was published in The New England Journal of Medicine and announced during the European Society for Medical Oncology Congress in Berlin on October 19, 2025.

The study underscores that hormone therapy alone has not improved survival in such cases, making this new combination a 'game changer' for aggressive prostate cancer patients.

Enzalutamide, a second-generation androgen receptor inhibitor, enhances suppression of androgen signaling, which is crucial for controlling prostate cancer progression, especially after resistance to initial treatments.

The results highlight the importance of PSA as a biomarker for early intervention to prevent metastatic disease and reduce healthcare costs.

Enzalutamide, already approved by the FDA and included in national treatment guidelines, appears to be a significant addition to standard care for high-risk patients, potentially changing clinical practice.

A clinical trial demonstrated that combining enzalutamide with hormone therapy reduces the risk of death by over 40% in men with high-risk recurrent prostate cancer after initial treatment.

This groundbreaking research offers renewed hope for men with recurrent prostate cancer, potentially transforming treatment standards worldwide.

The findings suggest a paradigm shift in managing recurrent prostate cancer, with future guidelines likely to incorporate this combination therapy to improve outcomes and quality of life.

The success of the study leverages existing regulatory approvals for enzalutamide, facilitating its rapid adoption into clinical practice, and underscores the value of translational research in cancer treatment.

The trial involved over 1,000 men across 17 countries, with participants randomized to receive hormone therapy alone, enzalutamide alone, or the combination, following them for eight years to gather long-term survival data.

This research emphasizes the role of targeted androgen receptor blockade in controlling disease progression and preventing skeletal metastases associated with prostate cancer.

The study involved more than 1,000 patients across 244 sites in 17 countries, all diagnosed with high-risk biochemically recurrent prostate cancer indicated by rapidly rising PSA levels after initial treatment.